John Overdeck’s Elevation Oncology ELEV Stock Holding History

John Overdeck’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-254,295	Closed	-$93.4K	–	3710
2025 Q2	$93.4K	Buy	254,295 +60,279	+31%	+$20.1K	﹤0.01%	3006
2025 Q1	$50.3K	Sell	194,016 -21,934	-10%	-$12.5K	﹤0.01%	3045
2024 Q4	$121K	Sell	215,950 -34	-0%	-$20	﹤0.01%	2944
2024 Q3	$130K	Buy	215,984 +156,528	+263%	+$232K	﹤0.01%	2865
2024 Q2	$161K	Buy	+59,456	New	+$224K	﹤0.01%	2769
2024 Q1	–	Sell	-364,892	Closed	-$196K	–	3101
2023 Q4	$196K	Sell	364,892 -73,696	-17%	-$39K	﹤0.01%	2844
2023 Q3	$291K	Buy	438,588 +14,693	+3%	+$14.9K	﹤0.01%	2503
2023 Q2	$644K	Buy	423,895 +349,937	+473%	+$923K	﹤0.01%	2206
2023 Q1	$141K	Buy	+73,958	New	+$95.4K	﹤0.01%	2624

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

John Overdeck's ELEV Position: Q3 2025 in Review

John Overdeck sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 254,295 shares — an estimated $93.4K sold.

John Overdeck first reported a position in ELEV in Q1 2023 and held it in 9 quarters. The position peaked at $644K in Q2 2023. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

John Overdeck reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
John Overdeck sold 254,295 Elevation Oncology shares in Q3 2025, an estimated $93.4K.
John Overdeck first reported a position in Elevation Oncology in Q1 2023 and held it in 9 quarters.
John Overdeck's Elevation Oncology position peaked at $644K in Q2 2023.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Two Sigma Investments's 13F filing for Q3 2025, filed 14 Nov 2025.